Molecular Toxicology, Inc. – Trademark Portfolio
Entity Type: 03
Molecular Toxicology, Inc. holds 4 U.S. trademarks filed with the United States Patent and Trademark Office (USPTO), with a strong focus on Class 1 (Chemicals) — 3 filings in this category. The portfolio also extends into Class 42 (Computer & Scientific) across 3 Nice Classification classes. Currently, 2 trademarks are registered. Notable registered marks include MOLTOX and MUTAZYME. The owner is based in Boone, NC.
157 Industrial Park Dr.
Boone, NC 28607
Showing of trademarks Trademarks
Trademark Classifications
Molecular Toxicology, Inc.'s trademark portfolio spans 3 Nice Classification classes, reflecting the scope of goods and services protected under their brand portfolio.
Chemical products for industry, science, photography, agriculture, horticulture and forestry
Scientific and technological services; industrial analysis and research services
Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes
Frequently Asked Questions
How many trademarks does Molecular Toxicology, Inc. have?
Molecular Toxicology, Inc. has 4 U.S. trademarks filed with the USPTO. Of these, 2 registered, 1 abandoned, 1 cancelled.
What trademark classes does Molecular Toxicology, Inc. file in?
Molecular Toxicology, Inc. files trademarks across 3 Nice Classification classes. The most active classes are Class 1 (Chemicals), Class 42 (Computer & Scientific), Class 5 (Pharmaceuticals). Class 1 covers chemical products for industry, science, photography, agriculture, horticulture and forestry.
What are Molecular Toxicology, Inc.'s most well-known trademarks?
Molecular Toxicology, Inc.'s registered trademark portfolio includes well-known marks such as MOLTOX and MUTAZYME. These are among 2 currently registered trademarks in the portfolio.
What is Molecular Toxicology, Inc.'s trademark registration success rate?
Molecular Toxicology, Inc. has a 50% trademark registration rate, with 2 out of 4 resolved applications resulting in successful registration. Currently, 0 applications are pending review.